Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Bionyra Pharma

Lucid Diligence Brief - BioPharma

Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief

Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…

by Eugenia Tsempera

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Endocrinology Today—June 30, 2026
Obesity Today—June 30, 2026
Endocrinology Today—June 23, 2026
Hematology Today—June 29, 2026
Oncology Today—June 29, 2026

Tags

arrhythmias benefits administration Bionyra Pharma Cardamyst clinical innovation Compositionality research consumer wearables Defactinib Diazoxide Choline Fast-Acting Meloxicam Gadoquatrane GenSight Biologics HA fillers Hamlet BioPharma Histology AI Huons incretins ivc thrombectomy Iza-bren Japanese Cedar Pollen Allergy market adoption mavacamten MEDVi Midjourney Medical Multi agonist therapy OHSU Paratyphoid vaccine PDE5 Inhibitors Pediatric Pancreatitis pharmaceutical strategy Pluristyx Public Health Emergency of International Concern PULSAR Portugal rosacea Rubraca Sernova Biotherapeutics Small lymphocytic lymphoma SSi Mantra Stem-cell diabetes therapy Syneos Health T-cell engager Tecarfarin Transcatheter Aortic Valve Replacement Vocal Biomarkers Vonoprazan

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Endocrinology Today—June 30, 2026
Obesity Today—June 30, 2026
Endocrinology Today—June 23, 2026
Hematology Today—June 29, 2026
Oncology Today—June 29, 2026

TAGS

arrhythmias benefits administration Bionyra Pharma Cardamyst clinical innovation Compositionality research consumer wearables Defactinib Diazoxide Choline Fast-Acting Meloxicam Gadoquatrane GenSight Biologics HA fillers Hamlet BioPharma Histology AI Huons incretins ivc thrombectomy Iza-bren Japanese Cedar Pollen Allergy market adoption mavacamten MEDVi Midjourney Medical Multi agonist therapy OHSU Paratyphoid vaccine PDE5 Inhibitors Pediatric Pancreatitis pharmaceutical strategy Pluristyx Public Health Emergency of International Concern PULSAR Portugal rosacea Rubraca Sernova Biotherapeutics Small lymphocytic lymphoma SSi Mantra Stem-cell diabetes therapy Syneos Health T-cell engager Tecarfarin Transcatheter Aortic Valve Replacement Vocal Biomarkers Vonoprazan

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy